JAMA Oncology APC and Open Access: Current AMA Pricing and When the Fee Is Worth It
JAMA Oncology's current APC is $6,000 for eligible gold OA articles. Standard publication is free, with delayed access after 12 months.
Next step
Choose the next useful decision step first.
Use the guide or checklist that matches this page's intent before you ask for a manuscript-level diagnostic.
JAMA Oncology publishing costs and open access options
APC is one cost. Funder mandates, institutional agreements, and access route timing all shape what you actually pay.
What shapes what you pay
- JAMA Oncology offers open access publishing. Check whether your institution has a read-and-publish agreement.
- Funder mandates (NIH, Wellcome, UKRI) may require immediate OA — verify compliance before choosing a subscription route.
- Accepted authors typically have 48-72 hours to choose their access route before proofs begin.
When OA is worth the cost
- When your funder or institution requires it — non-compliance can affect future funding.
- When your topic benefits from broad immediate access beyond institutional subscribers.
- JAMA Oncology's IF 20.1 means OA papers here have real citation upside.
Quick answer: JAMA Oncology currently lists a $6,000 article processing charge for eligible gold open-access articles. It is still a hybrid journal, so the standard route is $0, and JAMA says research articles become freely available on the JAMA Network website after 12 months. The fee question is real, but the bigger strategic question is whether the paper needs immediate open access badly enough to justify paying when the journal already offers a free delayed-access route. For the hub, see the JAMA Oncology journal page.
JAMA Oncology APC at a glance
Item | Current position |
|---|---|
Journal model | Hybrid |
Current APC | $6,000 |
Standard publication route | $0 |
Standard specialty-journal discount | None published |
Free public access without APC | Yes, after 12 months |
PubMed Central deposit | Yes for research articles |
OA-eligible research types | Original Investigations, Research Letters, Brief Reports |
2024 impact factor | 20.1 |
5-year impact factor | 24.7 |
SJR | 8.377 |
H-index | 193 |
Median first decision without peer review | 3 days |
Median first decision with peer review | 33 days |
If the real issue is whether the paper is strong enough for JAMA Oncology's editorial screen before you worry about the APC, run a JAMA Oncology submission readiness check. If the question is whether the manuscript is likely to be rejected before the fee matters, use the JAMA Oncology desk-rejection risk check.
What JAMA currently exposes publicly
The current JAMA Network Access Resource Center is much clearer than older secondary summaries. It says:
- the Specialty Journals APC is $6,000
- there are no discounts for Specialty Journals
- if an author cannot pay, the paper can still publish under the standard publishing agreement
- Research4Life eligibility can support full or partial waivers
The JAMA Oncology instructions and author pages add the second layer:
- JAMA Oncology is a hybrid journal
- eligible gold-OA article types include Original Investigations, Research Letters, and Brief Reports
- research articles become freely available after 12 months
- research articles are also deposited in PubMed Central
- the journal currently reports 20.1 impact factor, 8% acceptance rate, 3 days median first decision without review, and 33 days median first decision with review
That is enough to strip out two stale claims that still circulate in older web content:
- there is no current published specialty-journal discount to rely on
- there is no reason to treat a Vanderbilt pilot agreement as a general current planning assumption
Why the APC decision at JAMA Oncology is different
JAMA Oncology is not a fully open-access journal. That changes the economics.
If you choose the standard route:
- you pay $0
- the paper still publishes in JAMA Oncology
- the article becomes free to read on the JAMA Network site after 12 months
- research articles are deposited in PubMed Central
So the APC is not the price of publication. It is the price of immediate gold open access.
That makes JAMA Oncology different from a journal like JAMA Network Open, where the fee is built into the publication model from the start.
Metrics context behind the APC
Metric | Current figure | Why it matters with the APC |
|---|---|---|
Impact Factor | 20.1 | The journal still sits in the elite clinical-oncology tier |
5-year JIF | 24.7 | Long-run citation depth is stronger than the single-year headline |
SJR | 8.377 | Prestige-weighted influence remains very strong |
H-index | 193 | The archive has real long-run authority in oncology |
Acceptance rate | 8% | The fee is attached to a selective journal, not a volume model |
Median first decision without review | 3 days | Desk screening is fast and consequential |
Median first decision with review | 33 days | The peer-review path is quicker than many peers |
Annual views/downloads | 8.3M+ | Immediate OA can matter if broad clinical reach is the goal |
These numbers explain why the APC is defensible for some authors and unnecessary for others. JAMA Oncology is selective, clinically visible, and fast. But because the standard route is free, the APC only makes sense when immediate access changes the publication outcome you care about.
Long-run impact factor trend
Year | Impact factor |
|---|---|
2017 | 16.3 |
2018 | 22.4 |
2019 | 22.4 |
2020 | 31.7 |
2021 | 33.0 |
2022 | 33.0 |
2023 | 22.2 |
2024 | 20.1 |
The year-over-year move is negative. JAMA Oncology is down from 22.2 in 2023 to 20.1 in 2024. That does not make the journal weak. It does mean authors should pay for immediate access only when the access benefit is real, not because they assume the fee buys a stronger journal signal by itself.
Readiness check
Run the scan while the topic is in front of you.
See score, top issues, and journal-fit signals before you submit.
Open-access support, waivers, and what authors actually pay
The clean planning rule is:
- assume $6,000 for eligible gold-OA research articles
- assume $0 if you publish through the standard route
- then check whether a funder, institution, or waiver path changes the bill
Current public JAMA guidance supports three practical support paths:
- Research4Life country eligibility
- possible hardship handling if the author cannot pay
- funder or institutional support where available
What it does not support today is a published general specialty-journal discount. That is the point many older pages get wrong.
How JAMA Oncology compares with nearby options
Journal | OA cost structure | Metric profile | Practical fit |
|---|---|---|---|
JAMA Oncology | Hybrid, $6,000 APC or $0 standard route | IF 20.1, SJR 8.377 | Clinical oncology with strong population and practice relevance |
Hybrid with different ASCO economics | Higher flagship clinical-oncology prestige | Better for major practice-changing cooperative-group or trial work | |
Premium hybrid APC band | Stronger headline prestige | Better for globally consequential oncology studies | |
Hybrid | Strong ESMO clinical-oncology position | Better for some Europe-centered oncology audiences | |
Fully OA APC model | Broader general-medical OA lane | Better when immediate OA matters more than JAMA Oncology's editorial identity |
The strategic comparison is simple. JAMA Oncology is attractive because it gives authors a real choice:
- pay for immediate open access
- or publish in the same journal for free and accept delayed public access
What we see in pre-submission review work with JAMA Oncology manuscripts
In our pre-submission review work, the JAMA Oncology APC is usually worth paying only when the access rationale is concrete.
The journal already gives authors a workable free path. That means the APC should solve a specific problem, such as a funder mandate, institutional communications push, or strong immediate public-health audience need.
Fast screening matters more than the invoice. JAMA Oncology reports a median first decision without peer review of 3 days. For many manuscripts, the real risk is editorial fit, not APC budgeting.
The journal's lane is narrower than authors think. Strong oncology studies still get screened out if the manuscript does not look clinically important, population-relevant, or broadly useful beyond a narrow subspecialty slice.
That is why the best sequencing is usually:
- check journal fit
- check editorial readiness
- only then decide whether the APC has strategic value
Submit if / Think twice if
Submit and consider the APC worthwhile if:
- the manuscript clearly fits clinical oncology with broad readership implications
- an immediate OA mandate applies
- the funder or institution can cover the $6,000 fee
- rapid public access matters for policy, guidelines, or broad clinical visibility
Think twice if:
- the manuscript is only a marginal editorial fit and may not survive screening
- there is no immediate OA requirement
- the fee would come from personal or thin discretionary funds
- the delayed-free-access route already satisfies the practical dissemination goal
Practical verdict
JAMA Oncology's current APC planning number is $6,000, but that is only the price of immediate gold open access for eligible research article types.
Because JAMA Oncology still offers:
- a free standard route
- 12-month free public access
- PubMed Central deposit for research articles
the better question is not "can I pay the APC?" It is "does immediate OA change enough to justify paying it?"
Frequently asked questions
The current JAMA Network Access Resource Center lists the Specialty Journals article processing charge at $6,000. JAMA Oncology is a hybrid journal, so standard publication without gold open access is still available at no APC.
Yes. JAMA Oncology still offers the standard non-open-access route at no APC. Research articles also become freely available on the JAMA Network website after 12 months, and JAMA deposits research articles in PubMed Central.
The current JAMA Network pricing page says there are no discounts for Specialty Journals APCs. Separate waivers may still apply through Research4Life eligibility or hardship handling, but there is no standard specialty-journal discount published on the current pricing page.
The journal's current instructions say Original Investigations, Research Letters, and Brief Reports can be published gold open access. Other article types should not be assumed to use the same APC route.
It is easiest to justify when an immediate open-access mandate applies, institutional or funder support can cover the $6,000 fee, and the paper clearly fits JAMA Oncology's clinical-oncology and population-impact editorial lane.
Sources
Before you upload
Want the full picture on JAMA Oncology?
Scope, selectivity, what editors want, common rejection reasons, and submission context, all in one place.
These pages attract evaluation intent more than upload-ready intent.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Start here
Same journal, next question
Supporting reads
Want the full picture on JAMA Oncology?
These pages attract evaluation intent more than upload-ready intent.